Michał Walczak, CSO, was invited to speak about the therapeutic potenial of small molecule protein degraders at Cambridge Healthtech Institute's 14th Annual Drug Discovery Chemistry Conference.
The conference took place on 8-12 April 2019 in San Diego, CA, and hosted medicinal chemists from top pharma companies and from academia, such as GlaxoSmithKline, Astra Zeneca, Cellgene, Harvard Medical School and Dana-Farber Cancer Institute.
Share:
